

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad - 380 060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

Statement of Standalone and Consolidated Un-Audited Financial Results for the Quarter and Year Ended on 30-June-2020.

[Rs. in Lakhs]

Sr. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30/06/2020	31/03/2020	30/06/2019	31/03/2020	30/06/2020	31/03/2020	30/06/2019	31/03/2020
		(Un-Audited)	Refer Note 4	(Un-Audited)	(Audited)	(Un-Audited)	Refer Note 4	(Un-Audited)	(Audited)
1	Income								
	A) Revenue From Operations	10,103.27	7,526.20	9,458.95	37,608.83	10,379.36	7,846.68	9,681.26	38,649.05
	B) Other Income	197.49	530.93	157.95	1,213.10	179.79	418.74	129.44	1,104.01
	Total Income	10,300.76	8,057.12	9,616.90	38,821.92	10,559.16	8,265.42	9,810.70	39,753.06
2	Expenses								
	A) Cost of Material Consumed	2,010.38	2,045.39	2,353.61	10,197.06	2,702.30	2,768.41	2,198.05	13,372.61
	B) Purchase of Stock-In-Trade	2,673.37	1,785.87	1,998.03	9,066.22	1,680.21	1,178.71	2,034.45	5,759.95
	C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP	539.89	(270.22)	110.53	(585.51)	717.15	(435.91)	101.47	(841.33)
	D) Employee Benefits Expenses	1,206.77	1,249.72	1,439.69	5,489.90	1,292.06	1,374.72	1,524.47	5,865.38
	E) Finance Costs	33.66	30.80	64.41	198.36	67.39	(55.62)	64.59	201.76
	F) Depreciation and Amortisation Expense	140.55	136.29	139.50	546.94	187.82	182.56	184.68	732.62
	G) Other Expenses	1,628.81	1,941.06	1,811.17	7,504.28	1,770.80	2,099.12	1,918.03	7,938.85
	Total Expenses	8,233.43	6,918.90	7,916.94	32,417.27	8,417.72	7,111.99	8,025.75	33,029.83
3	Profit / (Loss) Before Exceptional Items & Tax (1-2)	2,067.33	1,138.22	1,699.97	6,404.66	2,141.43	1,153.43	1,784.95	6,723.23
4	Exceptional Items	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil
5	Profit / (Loss) after Exceptional items but Before Tax (3-4)	2,067.33	1,138.22	1,699.97	6,404.66	2,141.43	1,153.43	1,784.95	6,723.23
6	Tax Expense								
	A) Current Tax (Net)	536.00	202.23	511.33	1,471.93	583.76	219.20	515.59	1,572.58
	B) Deferred Tax (Net)	32.25	12.66	(27.82)	(23.63)	31.56	40.20	1.70	4.03
7	Profit / (Loss) For The Period (5-6)	1,499.08	923.32	1,216.45	4,956.35	1,526.12	894.03	1,267.66	5,146.62
8	Profit / (Loss) Attributable to Non-Controlling Interest	Nil	Nil	Nil	Nil	0.37	(0.39)	0.72	2.71
9	Profit / (Loss) Attributable to Owners of the Company	1,499.08	923.32	1,216.45	4,956.35	1,525.74	894.43	1,266.94	5,143.91
10	Other Comprehensive Income (Net Of Tax)	(10.99)	(47.20)	1.08	(43.94)	(11.55)	(48.66)	0.83	(46.18)
11	Total Comprehensive Income	1,488.10	876.12	1,217.53	4,912.41	1,514.57	845.37	1,268.49	5,100.44
12	Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each)	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00	2,000.00
13	Other Equity				28,449.49				29,308.88
	Earnings Per Share (of Rs. 10/- Each) (Not Annualised)								
	(a) Basic	7.50	4.62	6.08	24.78	7.63	4.47	6.33	25.72
	(b) Diluted	7.50	4.62	6.08	24.78	7.63	4.47	6.33	25.72

See accompanying notes to the Financial Results

NOTES:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their meeting held on August 20, 2020. The auditor have carried out an Limited Review of the said Financial Results.
- 2 These Financial Results have been prepared in accordance with Indian Accounting Standards (Ind-AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 Due to the on-going pandemic, There has been no significant adverse impact on business operations, except availability of raw materials from manufacturers as well as supply chain and distribution were marginally impacted initially due to the lockdown. The Company will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate impact on the business.
- 4 The figures for the quarter ended March 31, 2020 are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures up to the third quarter of the respective financial years.
- 5 Segment reporting as defined in IND-AS 108 is not applicable, since the Company has only one reportable segment i.e. Pharmaceuticals.
- 6 The figures for the previous periods have been regrouped / reclassified wherever necessary to confirm with the current period's classification.
- 7 Consolidated Results includes results of its subsidiaries.

For and on behalf of the Board of Directors

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: August 20, 2020